Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

331 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD.
Cutter G, Veneziano A, Grinspan A, Al-Banna M, Boyko A, Zakharova M, Maida E, Pasic MB, Gandhi SK, Everts R, Cordioli C, Rossi S. Cutter G, et al. Among authors: zakharova m. Mult Scler Relat Disord. 2020 May;40:101957. doi: 10.1016/j.msard.2020.101957. Epub 2020 Jan 20. Mult Scler Relat Disord. 2020. PMID: 32028117 Clinical Trial.
[Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study].
Boyko AN, Lashch NY, Sharanova SN, Zakharova MN, Trifonova OV, Simaniv TO, Lysogorskaya EV, Guryanova OE, Kotov SV, Iakushina TI, Lizhdvoy VY, Belova YA, Khabirov FA, Babicheva NN, Khaibullin TI, Granatov EV, Averyanova LA, Sazonov DV, Odinak MM, Trinitatsky YV, Tsukurova LA, Sergeeva AI, Ivanov RA, Shustova MS. Boyko AN, et al. Among authors: zakharova mn. Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(10 Pt 2):61-67. doi: 10.17116/jnevro201611610261-67. Zh Nevrol Psikhiatr Im S S Korsakova. 2016. PMID: 28139613 Clinical Trial. Russian.
[A comparative placebo-controlled clinical study on the efficacy and safety of interferon beta-1a for subcutaneous injections in patients with remitting multiple sclerosis: results of the first year of observations].
Boyko AN, Bosenko LP, Vasilovskiy VV, Volkova LI, Zakharova MN, Kotov SV, Lekomtseva EV, Negrich TI, Parshina EV, Patrusheva OP, Prokopenko SV, Sazonov DV, Timchenko PV, Trinitatskiy YV, Khabirov FA, Khavunka MY, Chichanovskaya LV, Sherman MA, Lin'kova YN, Zinkina-Orikhan AV, Tursunova KB. Boyko AN, et al. Among authors: zakharova mn. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(2. Vyp. 2):107-113. doi: 10.17116/jnevro201711722107-113. Zh Nevrol Psikhiatr Im S S Korsakova. 2017. PMID: 28617368 Clinical Trial. Russian.
[Provision of alemtuzumab safety is one of the main components of pharmacovigilance].
Khachanova NV, Bakhtiyarova KZ, Boyko AN, Vlasov YV, Davydovskaia MV, Evdoshenko EP, Zakharova MN, Malkova NA, Sivertseva SA, Spirin NN, Stolyarov ID, Schmidt TE, Khabirov FA. Khachanova NV, et al. Among authors: zakharova mn. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(8. Vyp. 2):82-87. doi: 10.17116/jnevro201811808282. Zh Nevrol Psikhiatr Im S S Korsakova. 2018. PMID: 30160673 Russian.
[Efficacy, tolerability and safety of the treatment with teberif: the results of a 2-year randomized clinical trial of treatment naïve patients with remitting multiple sclerosis, who have not received DMT, after switching from other interferon β-1a].
Boyko AN, Bosenko LP, Vasilovskiy VV, Volkova LI, Zakharova MN, Kotov SV, Lekomtseva EV, Negrich TI, Parshina EV, Patrusheva OP, Prokopenko SV, Sazonov DV, Timchenko LV, Trinitatskiy YV, Khabirov FA, Khavunka MY, Chichanovskaya LV, Sherman MA, Ivanov RA, Lin'kova YN, Stukalina EY, Zinkina-Orikhan AV, Obukhova IG. Boyko AN, et al. Among authors: zakharova mn. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(2. Vyp. 2):73-85. doi: 10.17116/jnevro20191192273. Zh Nevrol Psikhiatr Im S S Korsakova. 2019. PMID: 31156245 Clinical Trial. Russian.
[Updated recommendations of the Council of Experts on the use and safety of alemtuzumab (Lemtrada)].
Khachanova NV, Bakhtiyarova KZ, Boyko AN, Vlasov YV, Davydovskaya MV, Evdoshenko EP, Zakharova MN, Kotov SV, Popova EV, Sivertseva SA, Totolyan NA, Khabirov FA. Khachanova NV, et al. Among authors: zakharova mn. Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(3):82-91. doi: 10.17116/jnevro202012003182. Zh Nevrol Psikhiatr Im S S Korsakova. 2020. PMID: 32323949 Russian.
[New opportunities in the treatment of patients with multiple sclerosis (Resolution of the Council of Experts on April 23, 2022, Moscow, JSC «BIOCAD»)].
Spirin NN, Vlasov YV, Zakharova MN, Khachanova NV, Popova EV, Khabirov FA, Totolyan NA, Sivertseva SA, Goncharova ZA, Korsunskaya LL, Yakushina TI, Matvievskaya OV, Simaniv TO, Boyko AN. Spirin NN, et al. Among authors: zakharova mn. Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(7. Vyp. 2):84-88. doi: 10.17116/jnevro202212207284. Zh Nevrol Psikhiatr Im S S Korsakova. 2022. PMID: 35912562 Russian.
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC; ULTIMATE I and ULTIMATE II Investigators. Steinman L, et al. N Engl J Med. 2022 Aug 25;387(8):704-714. doi: 10.1056/NEJMoa2201904. N Engl J Med. 2022. PMID: 36001711 Clinical Trial.
331 results